DGX vs IMDX
DGX: A leading national provider of diagnostic testing and medical insights, delivering clinical laboratory services through an extensive network of patient centers and hospitals. IMDX: iMDx is disrupting the transplant diagnostics market by enabling hospitals to run their own donor-derived cell-free DNA (dd-cfDNA) tests in-house through a decentralized kitted model.
Side-by-side fundamentals
| Metric | DGX | IMDX | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $237.12 | $3.03 | |
| Market cap | $26.2B | $99M | |
| P/E as of 2026-10-20 | 25.17 | n/a | |
| PEG as of 2026-10-20, 3-year EPS CAGR to FY2025 | 7.96 | n/a | |
| Net margin FY2025, SEC XBRL | +9.0% | -1238.5% | DGX higher |
| Gross margin FY2025, SEC XBRL | n/a | +56.7% | |
| Operating margin FY2025, SEC XBRL | +14.1% | -1260.8% | DGX higher |
| ROE FY2025, SEC XBRL | +13.8% | n/a | |
| ROA FY2025, SEC XBRL | +6.1% | -195.0% | DGX higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.75 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +11.8% | +115.6% | IMDX higher |
| Revenue CAGR (3y) SEC XBRL | +3.7% | +61.8% | IMDX higher |
| Dividend yield as of 2026-09-03 | +1.4% | n/a | |
| Dividend streak (yrs) SEC XBRL | 11 | 0 | DGX higher |
| Beta as of 2026-09-03 | 0.15 | 0.91 | |
| 1-year return as of 2026-10-20 close | +24.5% | -48.6% | DGX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.